Harvard 21st Biennial Course in Urologic Oncology 2022

Name: Harvard 21st Biennial Course in Urologic Oncology 2022 - MeduStudent
SKU: MED-AMB03492
Price: 60.00 USD
Availability: InStock

$60.00

This Product is shared via google drive download link, So please share your correct Gmail id while placing the order .Please note that there are no CME points or certificate associated with this course Samples for Courses Can be found here : Free Samples Here!

Harvard 21st Biennial Course in Urologic Oncology 2022

This item: Harvard 21st Biennial Course in Urologic Oncology 2022

$60.00

ASCO SEP Qbank 2022

1 × ASCO SEP Qbank 2022

$40.00

Geriatric Oncology for the Advanced Practice Provider: Impacting Care Across the Globe – On Demand 2023

1 × Geriatric Oncology for the Advanced Practice Provider: Impacting Care Across the Globe – On Demand 2023

$25.00

2022 ASTRO Annual Meeting On Demand

1 × 2022 ASTRO Annual Meeting On Demand

$45.00

2023 Highlights of ASH in North America

1 × 2023 Highlights of ASH in North America

$30.00

2023 Critical Care Oncology Symposium – On Demand

1 × 2023 Critical Care Oncology Symposium – On Demand

$45.00

SKU: MED-AMB03492 Categories: Hematology / Oncology, Urology

Description

Harvard 21st Biennial Course in Urologic Oncology 2022

Biennial Course in Urologic Oncology

2022 Course Overview

Biennial Course in Urologic Oncology Beginning in 1982, the multidisciplinary Urologic Cancer Course was designed as a biennial course bringing together expertise from all the Harvard teaching hospitals in conjunction with invited world class experts in urologic oncology, medical oncology, and radiation oncology. Dr Marc B. Garnick led the course from 1982 to 1996 at which time Dr Jerome P. Richie assumed the leadership until 2014. Dr. Phillip W. Kantoff then led the course and subsequently in 2016 Dr Adam Kibel, Dr Toni Choueiri and Dr. Anthony V D’Amico co-led the course.

Biennial Course in Urologic Oncology In 2022 our keynotes will be delivered by 2 internationally renowned scholars. Dr. George Daley Dean of Harvard Medical School and Dr. Lindsey Baden Principle Investigator of the Covid Moderna Trial.

Who Should Attend

Primary Care Physicians
Specialty Physicians
Nurses
Nurse Practitioners
Pharmacists
Physician Assistants
Psychologists

Learning Objectives

Upon completion of this activity, participants will be able to:

Demonstrate the optimal management of oligometastatic prostate, bladder, renal cancer
Explain the role of immunotherapy in the management of bladder, prostate and renal cancer
Determine how to incorporate genomic classifiers, multiple parametric MRI, and clinical parameters into selecting optimal patients with prostate cancer for active surveillance or other definitive management approaches
Apply Level 1 evidence on the use of novel treatment paradigms and updated surveillance options for patients with prostate, renal, bladder, or testicular cancer
Apply novel minimally invasive treatments for GU malignancies including prostate, bladder and kidney cancer
Use multiparametric MRI, fusion biopsy and novel markers in men at risk for prostate cancer
Biennial Course in Urologic Oncology

THURSDAY, OCTOBER 13, 2022

7:15 – 8:00 AM

Registration

8:00 – 8:05 AM

Welcome
Anthony D’Amico

8:05 – 8:20 AM

Epidemiology and Genetics
Lorelei Mucci

8:20 – 8:35 AM

Screening in 2022: Role of PSA and Novel Biomakers
Adam Kibel

8:35 – 8:50 AM

Advanced in Multiparametric MRI for Diagnosis and Staging
Clare Tempany

8:50 – 9:05 AM

Interpreting Prostrate Biopsy Reports
Michelle Hirsch

9:05 – 9:30 AM

Expert Panel: Screening and Diagnosis
Moderator: Anthony D’Amico
Speakers: Michelle Hirsch, Adam Kibel, Lorelei Mucci and Clare Tempany

9:30 – 10:00 AM

Break

10:00 – 10:15 AM

Focal Ablation and Active Surveillance in Intermediate Risk Disease
Alexander Cole

10:15 – 10:30 AM

Radical Prostatectomy in Intermediate Risk Disease
Quoc-Dien Trin

10:30 AM – 10:45 AM

Hypofractionation and ADT use in Intermediate Risk Prostate Cancer
Neil Martin

10:45 – 11:00 AM

MRI Guided Radiation therapy
Jonathan Leeman

11:00 – 11:15 AM

Optimizing Systemic Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Anthony D’Amico

11:15 – 11:30 AM

Novel Approaches in the Preoperative Setting for the High-Risk Patient
Mary-Ellen Taplin

11:30 – 11:45 AM

Biomarker Based Clinical Trials and Prostate Cancer
Martin Gleave

11:45 AM – 12:15 PM

Expert Panel: Patient Selection
Moderator: Anthony D’Amico
Speakers: Alexander Cole, Martin Gleave, Jonathan Leeman, Neil Martin, Mary-Ellen Taplin, Quoc-Dien Trinh

12:15 – 1:00 PM

Lunch

1:00 – 1:15 PM

PET Imaging in the PSA Recurrent Setting-Diagnostics
Heather Jacene

1:15 – 1:30 PM

Treatment of Oligo Metastatic Disease, Integration of Surgery
Speaker: Martin Gleave

1:30 – 1:45 PM

Treatment of Oligo Metastatic Disease, Integration of Radiation
Paul Nguyen

1:45 – 2:00 PM

Precision Medicine in Prostate Cancer
Himisha Beltran

2:00 – 2:30 PM

Expert Panel: Updates in Diagnostics and Special Populations
Moderator: Adam Kibel
Speakers: Himisha Beltran, Martin Gleave, Heather Jacene and Paul Nguyen

2:30 – 2:45 PM

Break

2:45 – 3:00 PM

Adjuvant versus Salvage Radiation
Anthony D’Amico

3:00 – 3:15 PM

Management of the Rising PSA in the Patient with M0 Castrate Sensitive Prostate Cancer
Charles Ryan

3:15 – 3:30 PM

Management of Advanced Prostate Cancer in the Elderly
Alicia Morgans

3:30 – 3:45 PM

Survivorship and Side effects of ADT
Phil Saylor

3:45 – 4:00 PM

Management of Side Effects of Radical Prostatectomy in the Denovo and Recurrent Settings
Peter Chang

4:00 – 4:15 PM

Management of Side Effects of Radiation Therapy in the Denovo and Recurrent Settings
Daniel Schmidt

4:15 – 4:30 PM

Management of the Side Effects of Non-ADT Systemic Treatment for Prostate Cancer
Mark Pomerantz

4:30 – 5:00 PM

Expert Panel: Management of Treatment Related Toxicity and Recurrent Disease
Moderator: Adam Kibel
Speakers: Peter Chang, Anthony D’Amico, Alicia Morgans, Mark Pomerantz, Charles Ryan, Phil Saylor and Daniel Schmidt

FRIDAY, OCTOBER 14, 2022

8:00 AM – 8:15 AM

Management of the Rising PSA in the Patient with M0 Castrate Resistant Prostate Cancer
Atish Choudhury

8:15 – 8:30 AM

Personalizing Treatment Selection in Metastatic, Hormone-sensitive Prostate Cancer
Christopher Sweeney

8:30 – 8:45 AM

Immunotherapy for Prostate Cancer
Xiao Wei

8:45 – 9:00 AM

Novel Androgen Receptor Targeted therapy of Castrate Resistant M1 PC

9:00 – 9:15 AM

PET Imaging in the PSA Recurrent Setting – Therapeutics
Praful Ravi

9:15 – 9:45 AM

Expert Panel: Management of Metastatic Prostate Cancer
Moderator: Glenn Bubley
Speakers: Atish Choudhury, Praful Ravi, Charles Ryan, Christopher Sweeney, and Xiao Wei

9:45 – 10:15 AM

Break

10:15 – 10:45 AM

Special Lecture, Kidney Development and Wilms Tumor: Prospects for Regeneration
George Daley

10:45 – 11:00 AM

Role of Biomarkers in Diagnosis and Follow-up
Adam Feldman

11:00 – 11:15 AM

Management of Superficial Bladder Cancer
Angela Smith

11:15 – 11:30 AM

Genomics and its Role in the Management of Bladder Cancer
Joaquim Bellmunt

11:30 – 11:45 AM

Management of Upper Tract Disease
Matthew Mossanen

11:45 AM – 12:00 PM

Urinary Diversion after Cystectomy, Choices and Outcomes
Andrew Wagner

12:00 – 12:15 PM

Lymph Node Dissection and Approaches to Radical Cystectomy
Mark Preston

12:15 – 1:00 PM

Lunch

1:00 – 2:00 PM

Judah Folkman Lecture: Emerging Strategies in the Fight Against Covid-19
Lindsey Baden

2:00 – 2:15 PM

Genomic Predictors of Response to Chemotherapy
Kent Mouw

2:15 – 2:30 PM

Personalizing Bladder Cancer Treatment in Variant Histology
Angela Smith

2:30 – 2:45 PM

Neoadjuvant and Adjuvant Chemotherapy
Richard Lee

2:45 – 3:00 PM

Bladder Sparing Approaches
Jason Efstathiou

3:00 – 3:15 PM

Chemo and Immunotherapy for Advanced Urothelial Cancer
Joaquim Bellmunt

3:15 – 3:45 PM

Expert Panel: Bladder Cancer
Moderator: Adam Kibel
Speakers: Joaquim Bellmunt, Jason Efstathiou, Adam Feldman, Richard Lee, Kent Mouw, Matthew Mossanen, Mark Preston, Angela Smith and Andrew Wagner

3:45 PM – 4:00 PM

Break

4:00 – 4:15 PM

Management of Seminoma
Alok Tewari

4:15 – 4:30 PM

Management of Stage I non-seminoma
Timothy Clinton

4:30 – 4:45 PM

Updates in Radiation Therapy in Testis Cancer
Sophia Kamran

4:45 – 5:00 PM

Management of Advanced Disease-Chemotherapy
Christopher Sweeney

5:00 – 5:15 PM

Emerging Role of Genomics in Testis Cancer
Eliezer Van Allen

5:15 – 5:45 PM

Expert Panel: Testis Cancer
Moderator: Jerome Richie
Speakers: Timothy Clinton, Sophia Kamran, Christopher Sweeney, Alok Tewari and Eliezer Van Allen

SATURDAY, OCTOBER 15, 2022

8:00 – 8:15 AM

Tackling Tumor Metabolism in Renal Cell Carcinoma
Kimryn Rathmell

8:15 – 8:30 AM

Updated in the Pathology Classification of Renal Cell Cancer
Michelle Hirsch

8:30 – 8:45 AM

Role of Observation and Ablation for Small Renal Mass
Aria Olumi

8:45 – 9:00 AM

Radical or Partial Nephrectomy: Techniques and Innovations
Steven Chang

9:00 – 9:15 AM

Managing the Primary when Metastatic and Metastatectomy
Keyan Salari

9:15 – 9:30 AM

Adjuvant Strategies in RCC
Toni Choueiri

9:30 – 10:00 AM

Break

10:00 – 10:15 AM

Advanced Disease: First Line Options
Vincent Xu

10:15 – 10:30 AM

Advanced Disease: Post IO Setting
David McDermott

10:30 – 10:45 AM

Non Clear Cell RCC
Bradley McGregor

10:45 – 11:00 AM

Novel Targets Beyond Targeted Agents and IO Drugs
Xin Gao

11:00 AM – 12:00 PM

Expert Panel: Renal Cell Carcinoma
Moderator: Tonu Choueiri
Speakers: Steven Chang, Xin Gao, Michelle Hirsch, David McDermott, Bradley McGregor, Aria Olumi, Kimryn Rathmell, Keyan Salari and Vincent Xu

Biennial Course in Urologic Oncology